Glenmark Pharmaceuticals, for treating plaque psoriasis and rheumatoid arthritis in the country, has announced the launch of Adalimumab’s biosimilar under a licensing agreement with Zydus group firm Cadila Healthcare.

Glenmark in a statement said that, the biosimilar will be marketed by the company under the brand name ADALY. ADALY will be available to patients in India at a fraction of the global cost.

Sujesh Vasudevan, Glenmark India Formulations, Middle East and Africa President stated, “Being leader in the dermatology segment in India, ADALY is an important launch. The launch of this biosimilar will significantly enhance our presence in this segment.”

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week